Jiangzhi Zengdan Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a bulk non-sterile active pharmaceutical ingredient intended for downstream veterinary dosage-form manufacture. No harmonized model designation is attached to the nonproprietary name; the product is identified by the supplier batch code, the declared solid-state form, and the approved veterinary monograph where one exists. The material is received as a white to off-white free-flowing particulate and is not certified sterile at release. The declared dosage-form compatibility means that the same API can be qualified for solid oral, parenteral, and medicated-feed applications, but the finished-dose manufacturer assumes the burden of excipient compatibility, blend uniformity, bioburden control, and sterilisation or aseptic processing where required. Manufacturing should occur under veterinary GMP aligned with ICH Q7. Elemental impurity risk assessment follows the principles of ICH Q3D. Because the product is veterinary-only, human-grade pharmacopoeial monographs are not automatically applicable. If the supplier dossier lacks a dedicated method, the Chinese Veterinary Pharmacopoeia and relevant general chapters are used as the default analytical frame.

Impurity profiling for Jiangzhi Zengdan Powder should include related substances and degradation products. A suitable HPLC method uses a C18 column, 150 mm × 4.6 mm dimension, 5 µm particle size, and UV detection at the wavelength stated in the supplier monograph. A typical nonsterile veterinary API limit is total impurities not more than 1.0% by area normalisation, with any single unspecified impurity not more than 0.10% and specified impurities controlled at their individual listing. For injection-grade material, the total impurity limit may need to be tightened to 0.5% or lower if toxicological qualification data so require. Residual solvents are classified according to ICH Q3C: Class 1 solvents are controlled at the stated absence or threshold, Class 2 solvents such as acetonitrile or dichloromethane are limited to the approved maxima, and Class 3 solvents are typically controlled at not more than 0.5% w/w. The actual solvent profile must be obtained from the supplier because the final recrystallization solvent and drying conditions are process-specific. Published data for this specific product configuration are limited, and the supplier impurity validation report is the controlling document.

What Pharmacopoeial and Supplier-Defined Limits Apply to the Non-Sterile Powder?

The release specification is supplier-specific and must be read against the stated pharmacopoeial reference. Where no supplier monograph overrides, the representative acceptance matrix for nonsterile oral-grade powder can be used for initial screening, but it is not a certificate of analysis. Assay is reported on the dried or anhydrous basis, and the moisture limit depends on hydrate or solvate status. Parenteral use requires additional finished-product controls for bacterial endotoxin, subvisible particulates, and sterility.

The values in the table are default pharmaceutical expectations for nonsterile veterinary APIs and may be superseded by a tighter or looser supplier specification if justified by stability and target-species safety data. For tablet and capsule production, the particle-size specification should be selected by the dosage form: a d90 above 250 µm may be acceptable only if an upstream milling step is installed. For solution or injectable manufacture, the particle-size limit is not a surrogate for solubility, and dissolution must be confirmed in the intended vehicle.

In dry dosage manufacturing, the particle-size distribution of Jiangzhi Zengdan Powder controls tablet weight variation, capsule fill uniformity, and segregation in low-dose direct-compression formulations. A bimodal distribution may improve powder flow but can increase segregation when the API is blended with coarse excipients. High-shear granulation is normally run with an impeller speed of 1,000–2,000 rpm and a wet massing time of 6–12 min, but the optimum range for this product must be established by factorial experiments because published data specific to Jiangzhi Zengdan Powder are limited. The bulk powder should be passed through a 500–1,000 µm screen before blending to break agglomerates. Tablet compression is performed on a rotary press with a compression force that yields tablet hardness of 30–70 N for conventional round tooling; friability is checked according to Ph. Eur. 2.9.7 or USP <1216>. Blend uniformity is assessed according to USP <905>, with active recovery 90.0%–110.0% of label claim and RSD not more than 5.0% in development batches.

Injection-grade use imposes endotoxin, particulate, and bioburden controls beyond oral-powder release

When Jiangzhi Zengdan Powder is declared for injection or solution manufacture, the bulk release specification is not sufficient evidence of injectability. The finished product must be sterile, non-pyrogenic, and free from subvisible particles at the limits assigned to the route and species. Bacterial endotoxin is determined by USP <85> or Ph. Eur. 2.6.14; a typical veterinary parenteral limit is ≤0.5 EU/mg of active ingredient or ≤0.25 EU/mL of constituted solution, but the exact limit depends on maximum daily dose and target species. Subvisible particulates are measured with light obscuration or membrane microscopy under USP <788> for large-volume parenterals and USP <789> for small-volume parenterals. For solutions, the bulk powder must be dissolved or suspended in water for injection and passed through a 0.22 µm sterilising filter if terminal steam sterilisation is not feasible. Sterility is confirmed by membrane filtration under USP <71>. If the solution is not terminally sterilised, the whole process must be validated as aseptic and environmental monitoring must be in place. Published data for Jiangzhi Zengdan Powder in a sterile injection configuration are limited, so the manufacturer should generate pH, osmolality, and photostability data on the final formulation.

For premix and granule production, Jiangzhi Zengdan Powder is first dry-blended with a portion of a suitable carrier such as calcium carbonate, lactose, or rice hulls in a ribbon blender or double-cone blender. The premix should be step-milled through a 1,000–1,500 µm screen and mixed at low speed of 15–25 rpm for 10–15 min, followed by geometric dilution to prevent active segregation. If the powder is hygroscopic, the environment is kept below 50% RH and the finished premix is packaged in polyethylene-lined kraft bags with desiccant. Bulk density and tapped density are measured according to Ph. Eur. 2.9.34; a bulk density below 0.4 g/cm³ may require densification or dry granulation to reduce dusting and improve metering into feed. Feed homogeneity is assessed by sampling at least 10 locations and assaying active concentration; the coefficient of variation should not exceed 5.0% for a well-controlled premix. If the inclusion rate is less than 1.0% of the final feed, a step-down mixing procedure is mandatory to avoid hot spots. Published data for this specific API in target feed matrices are limited, so pilot-scale mixer validation is required for each carrier and inclusion rate.

Polymorph Identity, Solubility and Residual Process Controls

Polymorph identity is confirmed by X-ray powder diffraction and differential scanning calorimetry. The thermal profile should match the supplier reference; a melting endotherm or dehydration event that shifts by more than 2 °C indicates a solid-state change. Aqueous solubility is determined in buffers at pH 1.2, 4.5, and 6.8, with the measured value deciding whether a true solution is feasible or whether a suspension or cosolvent system is required. If solubility is below 1 mg/mL in the target vehicle, injectable formulation may require pH adjustment or a permitted solubilizer, and the final formula must be supported by stability data. Residual process controls include sieve residue, bulk density, and loss on drying after tray drying or vacuum drying. Drying is commonly performed at 40–60 °C under vacuum; higher temperatures may risk crystal form conversion or degradation, particularly when the batch has high residual solvent. Because no harmonized monograph is published for all dosage forms, these controls are supplier-specific and must be verified during technology transfer.

If the API Is Converted to Tablets or Capsules, Dry Granulation May Lower Segregation Risk

If Jiangzhi Zengdan Powder has a wide particle-size span or low bulk density, direct compression may cause unacceptable weight variation during long production runs. Under those conditions, dry granulation with a roller compactor is used to increase particle size and flow. The roller compactor is typically operated at roll pressure 20–80 bar, roll speed 2–8 rpm, and granulator screen 1.0–2.0 mm; the resulting granules should show a bulk density increase of 15–35% over the unprocessed powder. Tablet hardness, disintegration, and dissolution are evaluated using USP <701> disintegration and USP <711> dissolution or USP <2040> as appropriate. Capsule filling is performed on a dosator or tamping-pin machine; the fill weight is adjusted to deliver 95.0%–105.0% of target. If the powder is cohesive, addition of 0.5–1.0% colloidal silicon dioxide may improve flow, but the excipient must be shown not to bind the active ingredient or interfere with dissolution. Published data for Jiangzhi Zengdan Powder in dry granulation are limited; pilot studies with the actual vendor batch are therefore required.

Compared to a ready-to-use injection or a finished premix, Jiangzhi Zengdan Powder shifts the quality interface closer to the API source. The product differs from human-grade API in that veterinary-only release may follow veterinary pharmacopoeial appendices and may apply wider bioburden or elemental impurity limits where the target species and route support such limits. It differs from feed-grade active materials because the finished-dose manufacturer must still verify assay, related substances, dissolution, and residual solvents under ICH Q7 and the relevant veterinary GMP. The powder form is also distinct from direct-compression granules or spray-dried dispersions in that it requires additional particle engineering before tablet or capsule production. For solutions, the unformulated powder may require pH adjustment, filtration, and preservative screening that is not necessary with a proprietary ready-to-dilute concentrate. Batch-to-batch variability should be tracked using a control chart for particle size, moisture, and assay; a specification breach of more than 0.5% absolute assay deviation from the label claim is a major deviation in veterinary GMP. The product is not suitable for direct injection without further processing, and it should not be combined with amine-based additives or other reactive carriers unless forced-degradation and compatibility data exist.

The recommended storage condition for the unopened container is typically 25 °C with permitted excursions from 15–30 °C, protected from light and moisture. If the product is hygroscopic, the container closure system should include a desiccant and a liner, and the moisture content should be retested after each partial use. Accelerated stability testing at 40 °C ± 2 °C and 75% RH ± 5% RH for 6 months is used for oral powders; for injection-grade material, stress testing may include 60 °C for 10 days to identify degradation pathways. A re-test period of 24 months is common for nonsterile veterinary APIs, but the supplier stability protocol must be reviewed because published data for this specific product configuration are limited.